Update on ocrelizumab and PML.
Update on ocrelizumab and fatalities.
Update on ocrelizumab and malignancies.
Update on ocrelizumab and infections.
Update on ocrelizumab and COVID-19 pharmacovigilance data
Frequently asked questions on ocrelizumab and COVID-19.
Indications vary in different countries. The local prescribing information from your country is the primary source of information on the known and potential risks associated with ocrelizumab.
*Due to the nature of post-marketing adverse event reports, some of the investigations remain ongoing and therefore may be subject to change. For more information, please see the FAQs.